Most Liquid Pharmaceuticals Companies

Cash And Equivalents
Cash And EquivalentsEfficiencyMarket RiskExp Return
1ELTX Elicio Therapeutics
11.02 M
 0.01 
 4.17 
 0.05 
2TAK Takeda Pharmaceutical Co
533.53 B
(0.16)
 1.00 
(0.16)
3NVO Novo Nordisk AS
37.47 B
(0.20)
 2.67 
(0.54)
4MRK Merck Company
12.69 B
(0.19)
 1.22 
(0.23)
5BMY Bristol Myers Squibb
9.12 B
 0.12 
 2.01 
 0.25 
6SNY Sanofi ADR
6.9 B
(0.18)
 1.50 
(0.27)
7JNJ Johnson Johnson
5.37 B
(0.21)
 0.83 
(0.17)
8NVS Novartis AG ADR
4.64 B
(0.27)
 1.00 
(0.27)
9AZN AstraZeneca PLC ADR
4.52 B
(0.16)
 1.55 
(0.24)
10GSK GlaxoSmithKline PLC ADR
3.72 B
(0.18)
 1.52 
(0.27)
11ZTS Zoetis Inc
3.58 B
(0.18)
 1.33 
(0.23)
12RDY Dr Reddys Laboratories
2.93 B
(0.03)
 1.38 
(0.04)
13PFE Pfizer Inc
2.85 B
(0.08)
 1.55 
(0.13)
14LLY Eli Lilly and
2.07 B
(0.14)
 1.87 
(0.26)
15RPRX Royalty Pharma Plc
1.47 B
(0.14)
 1.06 
(0.14)
16ARVN Arvinas
1.27 B
(0.08)
 4.08 
(0.33)
17CGC Canopy Growth Corp
1.23 B
(0.12)
 5.19 
(0.60)
18SXTP 60 Degrees Pharmaceuticals,
2.25 M
 0.03 
 10.01 
 0.34 
19AVIR Atea Pharmaceuticals
684.48 M
(0.03)
 2.88 
(0.08)
20SUPN Supernus Pharmaceuticals
360.79 M
 0.11 
 1.86 
 0.20 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).